EP
ATNM icon

Essential Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

Essential Partners’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$5 – 2855
2025
Q4 		$5 Sell
4
-49
-92% -$71 ﹤0.01% 2761
2025
Q3 		$85 Sell
53
-168
-76% -$274 ﹤0.01% 2509
2025
Q2 		$309 Buy
+221
New +$331 ﹤0.01% 1833

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essential Partners's ATNM Position: Q1 2026 in Review

Essential Partners sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 4 shares — an estimated $5 sold.

Essential Partners first reported a position in ATNM in Q2 2025 and held it in 3 quarters. The position peaked at $309 in Q2 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Essential Partners reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Essential Partners sold 4 Actinium Pharmaceuticals shares in Q1 2026, an estimated $5.
  • Essential Partners first reported a position in Actinium Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Essential Partners's Actinium Pharmaceuticals position peaked at $309 in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Essential Partners's 13F filing for Q1 2026, filed 21 May 2026.